RecruitingNCT06805851

Impact of Depression on Thermoregulation

Thermoregulatory Responses to Heat Stress in Adults With Major Depressive Disorder With and Without Antidepressant Treatment

Sponsor

Penn State University

Enrollment

64 participants

Start Date

Mar 1, 2025

Study Type

OBSERVATIONAL

Conditions

Depression Selective Serotonin Reuptake Inhibitor

Summary

The purpose of this study is to determine if, compared to non-depressed adults, differences exist in skin blood flow and sweating responses to passive heat stress in adults with clinically diagnosed depression, those with depression who are prescribed and taking SSRIs and those with depression who are prescribed and taking SNRIs.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria11

Non-depressed adults aged 18-40 years;
OR adults aged 18-40 years with clinically diagnosed major depressive disorder according to DSM-V criteria not currently receiving antidepressant treatment;
OR adults aged 18-40 years with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a selective serotonin reuptake inhibitor;
OR aged 18-40 years adults with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a serotonin norepinephrine reuptake inhibitor;
All participants will be asymptomatic and no signs/symptoms of disease according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription (chest pain or pressure, dizziness, joint pain, and signs of cardiovascular disease);
Systolic blood pressure 140 mmHg and diastolic pressure 90 mmHg at screening;
Non-diabetic
Not taking any other medications that might affect the physiological variables of interest (beta blockers, tricyclic antidepressants, antipyretics, diuretics, etc.);;
Between the 20th and 80th percentiles for sex- and age-appropriate VO2max according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription;
English proficiency;
Capable of providing informed consent.

Exclusion Criteria16

BMI \> 35
Are pregnant or planning to become pregnant in the next 12 months;
Concurrently participate in another study involving physical activity or weight loss;
Plan to have surgery or relocate outside the area within the next year;
Medications that could alter cardiovascular or thermoregulatory responses to exercise (beta blockers, antipyretics, tricyclic antidepressants, diuretics, etc.);
Allergy to latex or adhesive;
Tobacco use;
Illegal/recreational drug use;
Exertional chest pain or musculoskeletal pain;
Contraindications to a maximal exercise test or an indication for early termination of the exercise test according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription;
Abnormal resting or exercise electrocardiogram (ECG);
Any bleeding disorders, gastric ulcers, allergies to NSAIDS, asthma, kidney/liver disorders, and taking any other anticoagulants;
History of Crohn's disease, diverticulitis, or similar gastrointestinal disease;
Co-morbid psychiatric disorders (psychosis, schizophrenia, bipolar disorder, panic disorder, obsessive compulsive disorder, etc.);
Active suicidal ideation (moderate or high suicidality);
Use of psychoactive or psychopharmacological drugs other than SSRI and SNRIs within one year of participating.

Locations(1)

Noll Laboratory

University Park, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06805851

Related Trials

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT0679339767 locations

Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care

NCT073648253 locations